U.S. Hotel and Resort REITs Stock News

Kymera Therapeutics stock edged up about 1% to US$105.48 after the Q2 print, a muted move for a biotech reporting US$65m in collaboration revenue and another quarter of sizeable losses. The market seems to be treating this as a steady, low drama update rather than a breakout moment. The key point for investors is the widening gap between a partnership-driven top line and continuing net losses of more than US$60m for the quarter. With cash of about US$1.5b and no more collaboration revenue...

With S&P 500 futures pressing against a key resistance zone and traders watching for either a breakout or a sharp mean reversion, short-term moves in large-cap U.S. stocks are under an intense spotlight. This kind of setup can create sudden winners and sudden laggards, which is why it matters if you care about timing. This article walks through 3 stocks exposed to the current news-driven tension around profit-taking and potential pullbacks. The 3 stocks below are just a starting sample, and...

Boston Scientific (NYSE:BSX) has initiated multiple large-scale recalls of cardiac ablation and access devices affecting hundreds of thousands of units globally in late July and August 2026. An FDA enforcement report cites a software anomaly in the TheraSphere 360 radiological platform, adding to the recent wave of product safety actions. The cluster of recalls and the FDA software enforcement report comes shortly after Boston Scientific's latest earnings and guidance updates. Consider...

Maplebear (CART) is back in focus after fresh earnings projections and sentiment shifts, while its Instacart unit’s AI-powered Caper smart trolleys with UK grocer Morrisons add an extra angle to the stock’s story. See our latest analysis for Maplebear. At a share price of US$45.35, Maplebear has given investors a 90 day share price return of 19.37%, while the 1 year total shareholder return is down 4.97%. This suggests that recent momentum has picked up after a softer year. If you are...

With the Federal Reserve debating its next move and markets bracing for the possibility of higher rates, many investors are rethinking how they get reliable income from stocks. Rising borrowing costs and inflation worries can unsettle growth stories, yet they also shine a spotlight on companies that focus on steady dividends and durable cash flows. This article walks through three stocks from a Defensive Dividend Stocks screener that appear positively exposed to the current rate backdrop and...

Q2 earnings event puts Black Hills in focus Black Hills (BKH) is in the spotlight after reporting second quarter 2026 results on August 5, with higher net income and earnings per share from continuing operations compared with a year earlier. See our latest analysis for Black Hills. Despite Black Hills reporting higher net income and earnings per share for the quarter and affirming its quarterly dividend on July 28, the stock shows mixed momentum, with a 1-year total shareholder return of...

Datavault AI (DVLT) is back on investor screens after amending its agreement with DataMeds AI to expand PharmacyChain licensing into broader healthcare and wellness, while restructuring its stake into common shares categorized as revenue. See our latest analysis for Datavault AI. Despite the expanded DataMeds AI agreement and recent management and investor events, Datavault AI’s short term momentum remains weak, with the share price down 24% in the last day and 72% year to date, alongside...

Why Hartford Insurance Group stock is in focus now Hartford Insurance Group (HIG) is back on investor radar after reporting second quarter 2026 results, updating its share repurchase activity and outlining a new buyback authorization alongside an acquisition in employee benefits. See our latest analysis for Hartford Insurance Group. Hartford Insurance Group’s latest earnings, buyback update and the planned acquisition of Equitable’s Employee Benefits business come after a period where the...

Douglas Emmett stock slipped 1.3% today to about US$11.80, which is a muted move for a real estate investment trust that just posted another quarter of unprofitable earnings. The emotional drag is clear. Investors are fixating on the reported loss per share and the weight of higher interest costs, while the core real estate engine tells a more balanced story. The real action sits in funds from operations and cash generation. Funds From Operations held in the mid US$70m range in the quarter...

In the second quarter of 2026, Cleveland-Cliffs Inc. reported sales of US$5,226 million and a net loss of US$145 million, both improved from a year earlier, while executing no additional share repurchases under its April 2024 buyback program. The results show sales growth alongside a smaller loss per share, indicating that cost and operational measures are narrowing the company’s losses even as it pauses incremental buybacks. With quarterly losses narrowing and sales higher, we’ll now...

Callaway Golf stock slipped about 2% today, even though the quarter just delivered one of the cleanest margin stories the company has put up in a while. Revenue for Q2 came in at US$612.2m, but the real headline was profit quality, with net income from ongoing operations at US$75.8m and management highlighting a sharp lift in gross margin. Investors came into this print after a strong 90 day run in the stock, so expectations were high. The reaction suggests nerves about sustainability, not...

EVgo stock dropped about 12% to US$1.53 into Thursday, extending a weak 30 day stretch and setting a low bar for this earnings print. The market focused on the red ink, with Q2 2026 delivering a basic loss per share of US$0.15 and net loss of US$20.8m. Looking past the near term pain presents a different picture. Charging network revenue was US$61m, and management is guiding to US$400m to US$430m of revenue for 2026 with an adjusted EBITDA loss that could narrow by year end. This quarter...

On August 3, 2026, Helus Pharma appointed Michael Halstead as Chief Executive Officer, bringing 25 years of biopharma experience and a record of leading major drug launches, large-scale integrations and multi billion-dollar M&A transactions. Halstead’s history of guiding companies from clinical development to full commercial operations may signal a shift in how Helus Pharma approaches growth, partnerships and capital allocation. We’ll now explore how bringing in a CEO with extensive...

Insulet stock just endured a 20% one day hit, sliding from about US$166.82 to roughly US$133.26, even as the latest quarter landed with solid headline strength. The company delivered Q2 revenue of US$801.7 million and basic earnings per share of US$1.37, supported by a trailing P/E of 24.6x that sits below the broader medical equipment peer group. The clash is clear: the tape is trading fear around the new type 2 diabetes rollout and customer retention, while the numbers show a business that...

Alphabet (GOOGL) is back in focus after CEO Sundar Pichai reshaped Google DeepMind’s leadership, moving Nobel Prize recipient Demis Hassabis into a new chief scientist role while he also continues in the chair position. See our latest analysis for Alphabet. Alphabet’s share price fell around 4% in the latest session after the DeepMind reshuffle. The stock still carries a 15% year to date share price return and a very strong 1 year total shareholder return of 85.36%. This suggests momentum has...

Clear Secure came into this print with a premium P/E, a soft three month share performance and a reputation as a high growth airport subscription story. The stock is up about 1.3% today, which is a muted response given the headline. Q2 delivered record free cash flow of US$189 million and adjusted EBITDA margin of 36.4%, finally clearing the 35% target management set back at the IPO. For a security and identity platform that investors often treat like a travel tollbooth, this quarter is...

Amgen just added roughly 5% in market value in a single session, with the stock jumping to about US$408, and the move tracks a quarter that gave investors something concrete to latch onto. Q2 revenue crossed US$10b and basic earnings per share landed above US$4. The bigger story sits on a longer time frame. Trailing 12 month earnings are now above US$16 per share and management has lifted full year guidance, which keeps the focus on whether this earnings run can support a valuation that still...

Traders pushed American Financial Group up about 4% to US$146.73 today after its Q2 report, rewarding a quarter that delivered punchy profitability rather than flashy top line growth. Core net operating earnings reached US$2.82 per share and property and casualty underwriting generated a Q2 record for pre tax operating income, with a specialty insurance combined ratio of 91.5%. Those are short term headlines. The bigger story for long term holders is that profit margins and return on equity...

Northeast Bank recently reported past fourth-quarter results for the period ended June 30, 2026, with net interest income rising to US$60.32 million and net income reaching US$34.34 million, alongside slightly higher net charge-offs of US$1.80 million and a cash dividend declaration of US$0.01 per share. The sharp year-over-year increase in earnings per share from continuing operations, even as charge-offs inched higher, highlights how stronger core lending profitability has supported...

L3Harris Technologies (LHX) recently signed two long term framework agreements with the Department of War and Lockheed Martin that aim to sharply expand propulsion production for PAC-3 MSE and THAAD missile defense systems. See our latest analysis for L3Harris Technologies. L3Harris Technologies’ latest PAC-3 MSE and THAAD agreements come after a period of mixed share price moves, with the stock down 6.03% on a year-to-date share price basis but delivering a 62.21% total shareholder return...

Teradyne stock has delivered a very strong 272.2% return over the past year, yet its valuation checks lean expensive rather than cheap. This raises questions about how much of the recent optimism is already reflected in the price. Over the last 1 year Teradyne has returned 272.2%, which puts extra focus on whether recent gains leave much room for further upside based purely on fundamentals. Strong demand for Teradyne's AI related test equipment can support optimistic expectations, while any...

Geron stock jumped 21.6% to US$1.63 on the first trading day after its Q2 release, a sharp move for a company long viewed as a discounted oncology developer with a long road to profitability. The headline is simple: solid revenue traction from RYTELO and stable operating spend have pulled losses into a narrower band, while the balance sheet still carries US$327m of cash. For a stock that came into earnings with modest double digit gains over 1, 3 and 6 months, this report has turned what was...

In the second quarter of 2026, Axon Enterprise reported revenue of US$904.39 million versus US$668.54 million a year earlier, while quarterly net income eased to US$29.43 million from US$36.12 million, and the company raised its full-year 2026 revenue growth guidance to a range of 32% to 34%. Although Axon’s quarterly profit margin compressed compared with the prior year, its stronger first-half earnings and higher full-year revenue outlook highlight how growing demand for its public safety...

Atlas Energy Solutions earnings trigger fresh focus on costs Atlas Energy Solutions (AESI) is back in the spotlight after its Q2 2026 report showed a higher net loss alongside only a modest change in revenue, putting cost pressures and margins firmly on investors’ radar. See our latest analysis for Atlas Energy Solutions. At a share price of $10.67, Atlas Energy Solutions has seen its short term share price return fall 22.8% over the past 30 days and 41.6% over 90 days, while the year to date...